Transcode Therapeutics, Inc. (RNAZ) - Dilution Analysis

S-3 filing: This prospectus relates to the possible resale or other disposition from time to time by the selling stockholders named in this prospectus of up to an aggregate of 15,955,543 shares of our Common Stock.

10-K filing | 0.9M shares outstanding

8-K filing: TransCode Therapeutics, Inc. entered into a Standby Equity Purchase Agreement with YA II PN, LTD, allowing the company to sell up to $14 million of common stock. The company also issued shares of Series A Preferred Stock as a payment-in-kind dividend.

S-3 filing: Transcode Therapeutics, Inc. intends to offer up to $150,000,000 in aggregate principal amount of common stock, preferred stock, debt securities, warrants and/or units through a shelf registration on Form S-3.

10-Q filing | 0.8M shares outstanding

8-K filing: TransCode Therapeutics, Inc. acquired ABCJ, LLC and issued common stock and preferred stock to DEFJ, LLC. DEFJ also agreed to purchase additional shares of Series B Preferred Stock for approximately $25 million. ($25.0M proceeds)

10-Q filing | 0.8M shares outstanding

8-K filing: Stock split 1-for-28 | Outstanding: 1,029,095 → 833,620

10-Q filing | 23.3M shares outstanding

10-K filing | 1.0M shares outstanding

8-K filing: TransCode Therapeutics, Inc. entered into a Placement Agency Agreement with ThinkEquity LLC to issue and sell 10,250,000 shares of common stock and 10,250,000 Common Warrants at $0.98 per share, with gross proceeds of approximately $10 million expected. ($10.05M proceeds)

S-1 filing: This prospectus relates to the resale by the selling stockholders of shares of common stock, shares of common stock issuable upon exercise of pre-funded warrants, and common shares underlying Series C and Series D warrants.

8-K filing: Stock split 1-for-33 | Outstanding: 17,265,658 → 696,233

8-K filing: TransCode Therapeutics, Inc. closed a private placement on December 2, 2024, issuing 5,710,000 shares of common stock and 15,510,160 pre-funded warrants, along with Series C and Series D warrants, for gross proceeds of approximately $8 million. ($7.99M proceeds)

10-Q filing | 17.3M shares outstanding

10-Q filing | 7.1M shares outstanding

8-K filing: TransCode Therapeutics, Inc. entered into a Placement Agency Agreement with ThinkEquity LLC to issue and sell 10,000,000 shares of common stock at $0.30 per share in a best efforts public offering, expected to close on July 24, 2024, with gross proceeds of $3.0 million before deducting fees and expenses. ($3.0M proceeds)

10-Q filing | 5.8M shares outstanding

10-K filing | 0.6M shares outstanding

8-K filing: TransCode Therapeutics, Inc. closed a public offering on January 22, 2024, selling 5,942,623 shares of common stock (or common stock equivalent) along with warrants to purchase 11,885,246 shares of common stock, at a price of $1.22 per share for gross proceeds of approximately $7.25 million. ($0.0M proceeds)

S-1/A filing: TransCode Therapeutics, Inc. is offering up to 3,472,222 shares of its common stock together with common stock purchase warrants to purchase up to 6,944,444 shares of common stock, or the common stock purchase warrants and pre-funded warrants to purchase shares of common stock, or the pre-funded warrants.

S-1/A filing: TransCode Therapeutics, Inc. is offering up to 1,500,000 shares of its common stock together with common stock purchase warrants to purchase up to 1,500,000 shares of common stock, or the common stock purchase warrants, and is also registering up to 3,090,000 shares of common stock issuable upon exercise of the common stock purchase warrants, pre-funded warrants and placement agent warrants pursuant to this prospectus.

8-K filing: Stock split 1-for-40 | Outstanding: 627,440 → 627,448

S-1 filing: TransCode Therapeutics, Inc. is offering up to 1,266,892 shares of its common stock together with common stock purchase warrants to purchase up to 1,266,892 shares of common stock, or the common stock purchase warrants, as well as pre-funded warrants to certain purchasers, and placement agent warrants.

8-K filing: TransCode Therapeutics, Inc. completed a registered direct offering of 5,000,000 shares of common stock at $0.242 per share, resulting in gross proceeds of $1.21 million before deducting fees and expenses; also issued warrants to the placement agent to purchase 300,000 shares of common stock at an exercise price of $0.3025 per share. ($1.21M proceeds)

10-Q filing | 10.7M shares outstanding

8-K filing: TransCode Therapeutics, Inc. closed a public offering of 700,000 shares of common stock and pre-funded warrants to purchase 16,163,000 shares of common stock, with gross proceeds of approximately $8.5 million, and issued Underwriter's Warrants to purchase 843,150 shares of common stock.

S-1/A filing: TransCode Therapeutics, Inc. is offering 11,479,408 shares of its common stock on a firm commitment basis and pre-funded warrants to purchase common stock.

S-1/A filing: TransCode Therapeutics, Inc. is offering 8,700,000 shares of its common stock and pre-funded warrants.

S-1 filing: TransCode Therapeutics, Inc. is offering shares of its common stock and pre-funded warrants. The common stock is listed on the Nasdaq Capital Market under the symbol "RNAZ." The last reported sale price of the common stock on August 28, 2023 was $1.67 per share.

10-Q filing | 2.0M shares outstanding

8-K filing: TransCode Therapeutics, Inc. entered into a Securities Purchase Agreement to sell 2,000,000 shares of common stock (or common stock equivalent) along with warrants at $3.50 per share for gross proceeds of approximately $7.0 million in a public offering expected to close on June 9, 2023. ($7.0M proceeds)

S-1/A filing: This S-1/A filing, dated 2023-06-06, details an offering of common stock and common stock purchase warrants. Up to 1,851,852 shares of common stock and warrants to purchase common stock. The company intends to use the net proceeds of this offering (i) to fund one or more clinical trials of TTX-MC138, our lead therapeutic candidate, including related IND enabling studies; (ii) to fund further research and development of our other therapeutic candidates; and (iii) for working capital and general corporate purposes.

S-1/A filing: This S-1/A filing registers common stock, common stock purchase warrants, and pre-funded warrants for sale, with the proceeds intended for clinical trials, research and development, and general corporate purposes.

8-K filing: Stock split 1-for-20 | Outstanding: 16,998,534 → 849,926

S-1 filing: This S-1 filing includes the offering of common stock, common stock purchase warrants, and pre-funded warrants for common stock.

10-Q filing | 14.4M shares outstanding

8-K filing: TransCode Therapeutics, Inc. entered into a Common Stock Purchase Agreement with White Lion Capital, LLC, allowing the Company to sell up to $1,081,307 of newly issued shares of common stock to White Lion, subject to certain conditions and limitations. ($1.08M proceeds)

10-K filing | 13.0M shares outstanding

S-1 filing: This S-1 filing describes an offering of common stock and pre-funded warrants with the intention to use the net proceeds to fund clinical trials, research and development, and for working capital and general corporate purposes.

S-3 filing: TransCode Therapeutics, Inc. intends to offer up to $150,000,000 in aggregate principal amount of its common stock, preferred stock, debt securities, warrants and/or units in one or more offerings.

S-1/A filing: TransCode Therapeutics, Inc. is offering 12,500,000 shares of common stock and up to 12,500,000 pre-funded warrants to purchase common stock.

S-1 filing: TransCode Therapeutics, Inc. is offering 12,500,000 shares of common stock and pre-funded warrants.

10-Q filing | 13.0M shares outstanding

10-Q filing | 13.0M shares outstanding

10-Q filing | 13.0M shares outstanding

10-K filing | 4.6M shares outstanding

10-Q filing | 4.6M shares outstanding

10-Q filing | 4.6M shares outstanding

S-1/A filing: This is a firm commitment initial public offering of common stock of TransCode Therapeutics, Inc.

S-1/A filing: This is a firm commitment initial public offering of common stock of TransCode Therapeutics, Inc.

S-1/A filing: This is a firm commitment initial public offering of common stock of TransCode Therapeutics, Inc.

S-1/A filing: This S-1/A filing registers the offering of common stock and warrants.

S-1/A filing: This is a firm commitment initial public offering of common stock of TransCode Therapeutics, Inc.

S-1 filing: This is a firm commitment initial public offering of common stock of TransCode Therapeutics, Inc.